Re:Viability dyes and doxorubicin

Timothy J Farley (tfarley@computer.net)
Thu, 14 Aug 1997 22:47:48 -0400

Mario suggested using FDA to determine viability for Gwen's doxorubicin
experiments.

I've observed during complement based cytotoxicity experiments lymphocytes
exhibiting near-normal light scatter, disrupted cellular membranes (PI+),
and active cytoplasmic enzyme activity (FDA+). Depending on timing, FDA
may not be an ideal indicator for viability. However, I have no other
suggestions.